A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
出版信息
Br Heart J. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
Abstract
摘要
相似文献
1
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.一项使用氯贝丁酯进行缺血性心脏病一级预防的合作试验。主要研究者委员会的报告。
Br Heart J. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
2
The clofibrate trial--the lipid hypothesis retested.氯贝丁酯试验——对脂质假说的重新检验
Med J Aust. 1979 Jun 2;1(11):490-1.
3
[Real or alleged risks of clofibrate derivatives and certain risks of their prohibition].[氯贝丁酯衍生物的实际或声称风险及其被禁止的某些风险]
Nouv Presse Med. 1979 Mar 31;8(15):1223-5.
4
Cholesterol, clofibrate and ischaemic heart disease. Facts and emotions around.胆固醇、氯贝丁酯与缺血性心脏病。相关的事实与情绪。
Cor Vasa. 1979;21(6):377-9.
5
6
7
Cholesterol, coronaries, clofibrate and death.胆固醇、冠状动脉、氯贝丁酯与死亡
N Engl J Med. 1978 Dec 14;299(24):1360-2. doi: 10.1056/NEJM197812142992409.
8
[Study of clofibrate. The opinion of Prof. D. Kritchevsky].
Minerva Cardioangiol. 1980 Nov;28(11):759-60.
9
Clofibrate and niacin in coronary heart disease.氯贝丁酯与烟酸治疗冠心病
JAMA. 1975 Jan 27;231(4):360-81.
10
Clofibrate for prevention of myocardial infarction.
Med Lett Drugs Ther. 1973 Apr 27;15(9):37-8.
引用本文的文献
1
Synthetic β-d-Glucuronides: Substrates for Exploring Glucuronide Degradation by Human Gut Bacteria.合成β - D - 葡萄糖醛酸苷：用于探索人类肠道细菌对葡萄糖醛酸苷降解作用的底物。
ACS Omega. 2024 Dec 20;10(1):1419-1428. doi: 10.1021/acsomega.4c09036. eCollection 2025 Jan 14.
2
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.超越低密度脂蛋白胆固醇：解读残余动脉粥样硬化性心血管疾病风险格局——聚焦高甘油三酯血症
Front Cardiovasc Med. 2024 Aug 7;11:1389106. doi: 10.3389/fcvm.2024.1389106. eCollection 2024.
3
Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy.关于使用相对风险统计数据描述高LDL胆固醇的所谓危害及降脂治疗益处的历史回顾。
Cureus. 2023 May 1;15(5):e38391. doi: 10.7759/cureus.38391. eCollection 2023 May.
4
[Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?].[因安全问题在其他国家撤回的药品：它们是否应继续在阿根廷药品市场上供应？]
Rev Fac Cien Med Univ Nac Cordoba. 2022 Sep 16;79(3):241-247. doi: 10.31053/1853.0605.v79.n3.35443.
5
Dietary Transitions and Health Outcomes in Four Populations - Systematic Review.四项人群中的饮食转变与健康结果——系统评价
Front Nutr. 2022 Feb 9;9:748305. doi: 10.3389/fnut.2022.748305. eCollection 2022.
6
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.超越降脂作用：他汀类药物对心脑血管疾病和癌症的影响
Pharmaceuticals (Basel). 2022 Jan 26;15(2):151. doi: 10.3390/ph15020151.
7
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?他汀类药物以外的口服降脂治疗：太老套过时了，还是仍然有用？
Curr Atheroscler Rep. 2021 Oct 14;23(12):74. doi: 10.1007/s11883-021-00971-y.
8
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap.二十碳五烯酸乙酯治疗高甘油三酯血症的疗效与安全性：综述
Eur Heart J Suppl. 2020 Oct 6;22(Suppl J):J21-J33. doi: 10.1093/eurheartj/suaa116. eCollection 2020 Oct.
9
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.PPAR 调节剂在健康与疾病中的探索与开发：临床证据的更新。
Int J Mol Sci. 2019 Oct 11;20(20):5055. doi: 10.3390/ijms20205055.
10
Medical therapeutics: mortality effects, uncertainty, and informed consent.医学治疗学：死亡率影响、不确定性与知情同意
Porto Biomed J. 2019 Feb 2;4(2):e35. doi: 10.1097/j.pbj.0000000000000035. eCollection 2019 Mar-Apr.
本文引用的文献
1
Reduction of serum-lipid and uric-acid levels by an orally active androsterone.口服活性雄甾酮降低血清脂质和尿酸水平
Lancet. 1962 Jun 23;1(7243):1321-3. doi: 10.1016/s0140-6736(62)92422-4.
2
RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY.冠心病的危险因素。评估几种血清脂质作为冠心病预测指标的研究；弗明汉姆研究。
Ann Intern Med. 1964 Nov;61:888-99. doi: 10.7326/0003-4819-61-5-888.
3
Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.雄酮与氯苯氧异丁酸乙酯口服活性组合的实验评估。
Lancet. 1962 Jun 23;1(7243):1323-6. doi: 10.1016/s0140-6736(62)92423-6.
4
Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate.氯苯丁酯对脂质代谢及分布的影响
Nature. 1962 Jun 9;194:948-9. doi: 10.1038/194948a0.
5
The electrocardiogram in population studies. A classification system.人群研究中的心电图。一种分类系统。
Circulation. 1960 Jun;21:1160-75. doi: 10.1161/01.cir.21.6.1160.
6
Estimation of the probability of an event as a function of several independent variables.作为多个独立变量的函数对事件概率的估计。
Biometrika. 1967 Jun;54(1):167-79.
7
Evaluation of survival data and two new rank order statistics arising in its consideration.生存数据的评估以及在考虑过程中出现的两个新的排序统计量。
Cancer Chemother Rep. 1966 Mar;50(3):163-70.
8
Serum triglycerides in health and in ischemic heart disease.
N Engl J Med. 1965 Oct 28;273(18):947-52. doi: 10.1056/NEJM196510282731802.
9
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.脂蛋白中的脂肪运输——机制与疾病的综合研究方法
N Engl J Med. 1967 Feb 2;276(5):273-81 concl. doi: 10.1056/NEJM196702022760507.
10
Clofibrate in coronary heart disease. Effect on morbidity and mortality.
JAMA. 1972 Feb 14;219(7):845-51.
Zotero 插件